Skip to Content
  • Previous Rank254
  • Revenues ($M)$13,003.00
  • Revenue Percent Change15.8%
  • Profits ($M)$2,940.00
  • Profits Percent Change47.1%
  • Assets ($M)$30,141.00
  • Employees7,467
  • Market Value — as of March 29, 2018 ($M)$67,101.60

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

Mark J. Alles
CEO Title
Chairman & Chief Executive Officer
Health Care
HQ Location
Summit, N.J.
Years on Fortune 500 List7

Celgene Rank History

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$13,003.0015.8%
Profits ($M)$2,940.0047.1%
Assets ($M)$30,141.00-
Total Stockholder Equity ($M)$6,921.00-
Market Value — as of March 29, 2018 ($M)$67,101.60-

Profit Ratios

Profit as % of Revenues22.6%
Profits as % of Assets9.8%
Profits as % of Stockholder Equity42.5%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)3.64
EPS % Change (from 2016)46.2%
EPS % Change (5 year annual rate)17.1%
EPS % Change (10 year annual rate)29.7%

Total Return

Total Return to Investors (2017)-9.8%
Total Return to Investors (5 year, annualized)21.6%
Total Return to Investors (10 year, annualized)16.3%